Menue

Publications

Authors Seib, P. ; Tsurkan, M. ; Freudenberg, U. ; Kaplan, D. L. ; Werner, C.
Title Heparin-modified polyethylene glycol microparticle aggregates for focal cancer chemotherapy
Date 21.10.2016
Number 52428
Abstract Focal cancer therapy can improve clinical outcomes. Here, we evaluated injectable heparin-containing hydrogel material loaded with doxorubicin as a focal breast cancer therapy. We utilized a binary heparin/polyethylene glycol (PEG) hydrogel that was processed post synthesis into hydrogel microparticle aggregates to yield a readily injectable hydrogel. When loaded with doxorubicin, the injectable hydrogel microparticle aggregates had excellent short- and long-term anticancer activity against human breast cancer cells in vitro. Efficacy as a focal anticancer therapy was also evaluated in vivo by local injection of the doxorubicin-loaded PEG-heparin hydrogel microparticle aggregates into mice with established human orthotopic breast tumors. Animals showed significant antitumor responses by reduction in both primary tumor growth and metastasis when compared to animals that received the equivalent doxorubicin dose via an intravenous bolus injection. Overall, PEG-heparin hydrogel microparticle aggregates are emerging as a potential anticancer drug delivery system for focal therapy.
Publisher ACS Biomaterials Science & Engineering
Wikidata
Citation ACS Biomaterials Science & Engineering 2 (2016) 2287-2293
DOI https://doi.org/10.1021/acsbiomaterials.6b00495
Tags breast cancer hydrogel microparticle drug delivery

Back to list